Loading
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.
Regular session
$9.05
−$0.17 · -1.84%
Regular session · ET · Market data may be delayed.
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.
Day range
Current $9.05
52-week range
Current $9.05
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
7
Overpriced
Sentiment
64
Bullish
Risk
56
Elevated Risk
Momentum
71
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.
Day range
Current $9.05
52-week range
Current $9.05
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2.8M USD | 4.53M USD | 5.72M USD | 5.75M USD | 4.78M USD |
| Cost of goods sold | 11.74M USD | 62.46M USD | 47.57M USD | 58.91M USD | 44.59M USD |
| Gross profit | −8.94M USD | −57.93M USD | −41.85M USD | −53.16M USD | −39.8M USD |
| Research and development | 81.42M USD | 63.86M USD | 48.07M USD | 58.91M USD | 44.59M USD |
| Selling, general, and administrative | 35.06M USD | — | — | — | — |
| Operating expenses | 115.78M USD | 50.96M USD | 73.67M USD | 53.59M USD | 35.43M USD |
| Interest expense | 209K USD | 565K USD | 1.01M USD | 972K USD | 3.43M USD |
| Depreciation and amortization | 11.74M USD | 13.39M USD | 14M USD | 13.1M USD | 6.65M USD |
| Operating income | −124.72M USD | −108.89M USD | −115.52M USD | −106.75M USD | −75.24M USD |
| Net income | −115.18M USD | −103.11M USD | −110.57M USD | −104.9M USD | −100.96M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$13.60
50.28% upsideFunds reporting this stock among their holdings, ordered by reported position size.
ARK Genomic Revolution ETFARKG99.2M4.70%1.56B USD0.75%$48.65-2.97%
State Street SPDR S&P Biotech ETFXBI53.21M0.52%10.08B USD0.35%$147.15-2.05%
Vanguard Morningstar Total Stock Market ETFVTI40.34M0.00%2.3T USD0.03%$379.55-0.39%
iShares Russell 2000 ETFIWM36.37M0.05%78.56B USD0.19%$274.83-1.04%
Vanguard Extended Market ETFVXF14.4M0.01%95.4B USD0.05%$231.42-0.89%
iShares Russell 2000 Growth ETFIWO10.82M0.08%14.25B USD0.24%$350.64-1.33%
iShares Biotechnology ETFIBB10.31M0.10%10.4B USD0.44%$198.03-2.61%
Schwab U.S. Small-Cap ETFSCHA8.63M0.04%21.7B USD0.03%$32.295-0.97%ARK Genomic Revolution ETFARKGState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
